On Thursday, Jazz Pharmaceuticals (NASDAQ:JAZZ) shares, a $7.3 billion pharmaceutical company with an impressive InvestingPro Financial Health score of "GREAT," received a reaffirmation of its Overweight rating and a price target of $163.00 from Piper Sandler.
The firm's analyst highlighted the recent accelerated FDA approval of Ziihera (zanidatamab), Jazz's HER2-targeted bispecific antibody, for adults with previously treated, unresectable, or metastatic HER2-positive biliary tract carcinoma (BTC). The management call primarily focused on the opportunities presented by this development.
Ziihera will be introduced to the market with a list price of $7,110 for two 300 mg vials, which translates to approximately $35,500 for a 28-day treatment cycle. The treatment targets a specific U.S. patient population, estimated to be around 3,000 patients, for first-line (1L) and second-line (2L) HER2+ BTC.
Although this market size is relatively small and not expected to be transformational for Jazz's revenue, which currently stands at nearly $4 billion annually with an exceptional gross profit margin of 92.6%, it is seen as an addition to the company's growth in the oncology segment.
The oncology portfolio of Jazz Pharmaceuticals has also been bolstered by positive data from Zepzelca in extensive-stage small cell lung cancer. The analyst from Piper Sandler believes that the recent developments add another layer of growth for the company's oncology segment.
According to InvestingPro analysis, the company's strong financial position is reflected in its healthy free cash flow yield of 15% and robust current ratio of 4.26x, suggesting ample resources for continued portfolio expansion. For deeper insights into Jazz's financial health and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
Looking forward, there is anticipation for the second quarter of 2025 data on Ziihera in first-line HER2+ gastroesophageal adenocarcinoma (GEA). This potential expansion in treatment indications could provide additional value to Jazz Pharmaceuticals, which currently appears undervalued based on InvestingPro Fair Value analysis. The company's shares are currently trading at an enterprise value to EBITDA ratio of 7.2x, suggesting potential upside opportunity for investors.
The reiteration of the Overweight rating by Piper Sandler underscores the firm's positive outlook on Jazz Pharmaceuticals' stock, taking into account the recent FDA approval and the potential for future growth in the oncology market.
In other recent news, Jazz Pharmaceuticals has made strategic financial moves, amending its credit agreement to increase its revolving credit facility from $500 million to $885 million and extend the maturity date to November 26, 2029. This allows the company greater financial flexibility.
In addition, the company has seen significant growth in the patient base for its medication, Xywav, leading to an increase in its price target from $154 to $162 by Baird. However, Jefferies adjusted its stock price target for Jazz Pharmaceuticals to $160, based on the company's attractive valuation and projected five-year revenue and earnings per share growth rates.
Moreover, Jazz Pharmaceuticals received the U.S. Food and Drug Administration's accelerated approval of zanidatamab, a therapy for patients with previously treated, unresectable or metastatic HER2+ biliary tract cancer. This led TD Cowen to reiterate a Buy rating and a $195.00 price target for the company's stock.
The company is also awaiting phase 3 topline Progression-Free Survival results for zanidatamab, which could potentially influence its trajectory. These are the recent developments for Jazz Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.